$697 Million is the total value of Soleus Capital Management, L.P.'s 72 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EDAP | Buy | EDAP TMS S Asponsored adr | $54,733,024 | +35.7% | 5,134,430 | +5.0% | 7.85% | +43.3% |
| BCAB | Buy | BIOATLA INC | $34,818,275 | +33.0% | 4,220,397 | +24.1% | 5.00% | +40.4% |
| SRDX | Buy | SURMODICS INC | $26,453,611 | +13.2% | 775,311 | +0.9% | 3.80% | +19.6% |
| VCEL | Buy | VERICEL CORP | $23,942,981 | +175.9% | 908,997 | +143.0% | 3.44% | +191.3% |
| IRMD | Buy | IRADIMED CORP | $21,076,163 | +2.4% | 745,004 | +8.8% | 3.02% | +8.1% |
| ORGO | Buy | ORGANOGENESIS HLDGS INC | $19,806,639 | -5.8% | 7,363,063 | +13.5% | 2.84% | -0.6% |
| PCVX | Buy | VAXCYTE INC | $18,602,203 | +130.9% | 387,950 | +15.6% | 2.67% | +143.7% |
| CELC | Buy | CELCUITY INC | $16,955,294 | +280.4% | 1,210,228 | +172.6% | 2.43% | +301.3% |
| CCCC | Buy | C4 THERAPEUTICS INC | $14,400,974 | +13.9% | 2,440,843 | +69.3% | 2.07% | +20.3% |
| NARI | Buy | INARI MED INC | $14,272,398 | +93.4% | 224,550 | +121.0% | 2.05% | +104.2% |
| EXAS | Buy | EXACT SCIENCES CORP | $14,224,223 | +202.3% | 287,300 | +98.4% | 2.04% | +219.4% |
| HUM | Buy | HUMANA INC | $13,701,083 | +98.9% | 26,750 | +88.4% | 1.97% | +110.0% |
| INBX | Buy | INHIBRX INC | $11,785,361 | +80.4% | 478,302 | +31.4% | 1.69% | +90.4% |
| KROS | Buy | KEROS THERAPEUTICS INC | $11,194,230 | +103.8% | 233,116 | +59.7% | 1.61% | +115.3% |
| EPIX | Buy | ESSA PHARMA INC | $9,750,868 | +102.9% | 3,869,392 | +46.5% | 1.40% | +114.2% |
| HCA | New | HCA HEALTHCARE INC | $8,290,618 | – | 34,550 | +100.0% | 1.19% | – |
| THTX | Buy | THERATECHNOLOGIES INC | $7,767,876 | -59.1% | 8,799,125 | +9.9% | 1.11% | -56.8% |
| BCYC | New | BICYCLE THERAPEUTICS PLCsponsored ads | $7,648,640 | – | 258,400 | +100.0% | 1.10% | – |
| AXGN | Buy | AXOGEN INC | $7,544,860 | +48.9% | 755,998 | +77.9% | 1.08% | +57.3% |
| RNA | New | AVIDITY BIOSCIENCES INC | $6,878,900 | – | 310,000 | +100.0% | 0.99% | – |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC | $6,411,107 | +0.5% | 137,814 | +12.0% | 0.92% | +6.1% |
| AVTE | New | AEROVATE THERAPEUTICS INC | $6,361,587 | – | 217,119 | +100.0% | 0.91% | – |
| OFIX | New | ORTHOFIX MED INC | $6,062,509 | – | 295,300 | +100.0% | 0.87% | – |
| FDMT | New | 4D MOLECULAR THERAPEUTICS IN | $5,656,887 | – | 254,700 | +100.0% | 0.81% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $5,599,000 | – | 220,000 | +100.0% | 0.80% | – |
| STAA | New | STAAR SURGICAL CO | $5,349,108 | – | 110,200 | +100.0% | 0.77% | – |
| ETNB | Buy | 89BIO INC | $4,824,670 | +152.5% | 379,000 | +14.8% | 0.69% | +166.2% |
| DXCM | Buy | DEXCOM INC | $4,529,600 | +135.9% | 40,000 | +67.8% | 0.65% | +149.0% |
| AXSM | New | AXSOME THERAPEUTICS INC | $3,856,500 | – | 50,000 | +100.0% | 0.55% | – |
| BLI | New | BERKELEY LTS INC | $3,564,400 | – | 1,330,000 | +100.0% | 0.51% | – |
| NPCE | Buy | NEUROPACE INC | $3,529,814 | -59.7% | 2,369,003 | +1.5% | 0.51% | -57.4% |
| PHVS | New | PHARVARIS N V | $3,487,500 | – | 310,000 | +100.0% | 0.50% | – |
| RXDX | New | PROMETHEUS BIOSCIENCES INC | $3,421,000 | – | 31,100 | +100.0% | 0.49% | – |
| TGTX | New | TG THERAPEUTICS INC | $2,815,540 | – | 238,000 | +100.0% | 0.40% | – |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $2,574,760 | – | 236,000 | +100.0% | 0.37% | – |
| TXG | New | 10X GENOMICS INC | $2,550,800 | – | 70,000 | +100.0% | 0.37% | – |
| New | VENTYX BIOSCIENCES INC | $2,262,510 | – | 69,000 | +100.0% | 0.32% | – | |
| NEOG | New | NEOGEN CORP | $2,185,505 | – | 143,500 | +100.0% | 0.31% | – |
| New | PARDES BIOSCIENCES INC | $2,112,500 | – | 1,250,000 | +100.0% | 0.30% | – | |
| PEN | New | PENUMBRA INC | $2,068,878 | – | 9,300 | +100.0% | 0.30% | – |
| LUNG | New | PULMONX CORP | $598,530 | – | 71,000 | +100.0% | 0.09% | – |
| KIDS | New | ORTHOPEDIATRICS CORP | $296,823 | – | 7,471 | +100.0% | 0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ESSA PHARMA INC | 16 | Q3 2023 | 10.8% |
| IRADIMED CORP | 16 | Q3 2023 | 5.8% |
| XENON PHARMACEUTICALS INC | 15 | Q3 2023 | 2.9% |
| IVERIC BIO INC | 14 | Q1 2023 | 6.5% |
| SURMODICS INC | 14 | Q3 2023 | 4.7% |
| NATERA INC | 13 | Q3 2023 | 3.9% |
| DEXCOM INC | 13 | Q2 2023 | 4.2% |
| NOVOCURE LTD | 13 | Q3 2023 | 3.4% |
| CRISPR THERAPEUTICS AG | 13 | Q2 2023 | 2.6% |
| LYRA THERAPEUTICS INC | 13 | Q3 2023 | 1.0% |
View Soleus Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Soleus Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.